AMERICAN DIABETES RESEARCH AND TREATMENT FUND (EIN 455567456) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2012

Legal Domicile

Principal Officer

VIVIAN MONTANO

Phone

7605405034

Tax Period

2024-10-01 to 2025-09-30

AMERICAN DIABETES RESEARCH AND TREATMENT FUND, founded in 2012, is a small nonprofit in the Diseases & Disorders sector that reported $239K in total revenue in fiscal year 2024. Revenue surged 23% from the prior year, signaling strong growth momentum.

Mission

The Organization awards grants for diabetes research and programs. It provides for shipments of humanitarian aids, supplies, and foods to impoverished communities to help fight diabetes and other degenerative diseases.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $239,161

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $239,161

Expense Breakdown

Grants Paid $216,651

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $236,324

Other Expenses $21,222

TOTAL EXPENSES $237,873

Year-over-Year Comparison

	2024	2023	Change
Revenue	$239,161	$194,336	+0.2%
Expenses	$237,873	$199,197	+0.2%
Net Income	$1,288	$-4,861	-1.3%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
VIVIAN MONTANO	PRESIDENT	012.00	Officer Director Key Emp	$0	$0	$0
NATASHA L EVANS	SECRETARY / TREASURER	002.00	Officer Director	$0	$0	$0
JAVIER LUGO	V PRESIDENT	002.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$239,161	$237,873	$15,673	$1,288
2024	$194,336	$199,197	$14,385	$-4,861
2023	$214,026	$225,821	$19,246	$-11,795
2022	$247,806	$244,287	$31,041	$3,519
2021	$237,639	$242,163	$29,104	$-4,524
2020	$236,143	$231,883	$33,628	$4,260
2019	$224,572	$225,006	$29,368	$-434
2018	$663,656	$672,340	$29,802	$-8,684

AMERICAN DIABETES RESEARCH AND TREATMENT FUND